1188 related articles for article (PubMed ID: 28764676)
1. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
2. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
4. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of survivals and toxicities between young and elderly patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy.
Wang W; Liu X; Meng Q; Zhang F; Hu K
Taiwan J Obstet Gynecol; 2019 May; 58(3):364-369. PubMed ID: 31122526
[TBL] [Abstract][Full Text] [Related]
6. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
Hu K; Wang W; Liu X; Meng Q; Zhang F
Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
[TBL] [Abstract][Full Text] [Related]
7. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.
Tian T; Gao X; Ju Y; Ding X; Ai Y
Arch Gynecol Obstet; 2021 Mar; 303(3):793-801. PubMed ID: 33009996
[TBL] [Abstract][Full Text] [Related]
10. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
11. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
13. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and benefit of concurrent chemoradiotherapy for elderly patients with uterine cervical cancer.
Nosaka K; Shibata K; Utsumi F; Yoshida K; Niimi K; Sekiya R; Suzuki S; Kajiyama H; Kikkawa F
Tumori; 2016 Dec; 102(6):600-605. PubMed ID: 27443893
[TBL] [Abstract][Full Text] [Related]
19. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of concomitant chemoradiotherapy incorporating high-dose-rate brachytherapy to treat locally advanced cervical cancer.
Lee HJ; Kim YS; Shin SS; Nam JH; Kim YT; Han S; Choi EK
Tumori; 2012; 98(5):615-21. PubMed ID: 23235757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
